AI-Powered Ophthalmic Service Provider ZhenHealth Secures Tens of Millions of RMB in Series A Funding Led by Jinpu Industrial Investment Fund

Recently, Zhizhen Hulian, an AI-powered ophthalmology service provider, announced the completion of its tens-of-millions-of-yuan Series A financing round, invested by Jinpu Industrial Investment Fund. Evolution Capital served as the exclusive financial advisor for this round. The proceeds will be used for network expansion, sales system upgrades, and product research and development.

Zhenzhi Interconnect entered the market through ophthalmology, leveraging its extensive big data accumulation in ophthalmic imaging and technological advantages in artificial intelligence to provide precise, high-quality, and affordable intelligent screening services for eye diseases. It offers solutions for four major application scenarios: remote image reading, remote consultation, remote screening, and clinical tools, and has launched the world’s first portable intelligent fundus camera.

China faces a severe shortage of ophthalmologists. Currently, there are nearly 140 million patients with diabetes, 27 million with diabetic retinopathy, 16 million with glaucoma, and 30 million with macular diseases in China. Among them, 87% of diabetic patients seek medical care at healthcare institutions below the county level. However, there are only 38,000 ophthalmologists nationwide, most of whom are concentrated in medical institutions in large and medium-sized cities, far insufficient to provide treatment for grassroots patients. The market for ophthalmic services is vast.

Zhizhen Interconnect has significantly addressed the shortage of specialist physicians at the primary care level through its “AI + Hardware” service model. In terms of AI and algorithms, Zhizhen Interconnect collaborates with authoritative medical institutions and experts to build a fundus image database containing tens of millions of lesion cases, with both data scale and image quality ranking among the world’s leading standards. This effort has established a competitive advantage in AI algorithms for fundus imaging across dozens of disease types. On the hardware front, the company utilizes its proprietary AI-powered fundus cameras, which are simple, intelligent, portable, and cost-effective. Patients at primary care facilities need only undergo a straightforward fundus photography procedure to receive screening reports, thereby supporting the treatment and management of chronic diseases.

Regarding the team, Founder and CEO Dai Liming has over 10 years of experience at Baidu, where he held senior management positions in the Commercial, Operations, Risk Control, and User Departments. The company’s core team hails from leading Chinese internet companies such as Baidu, Tencent, and Xiaomi, bringing extensive practical and managerial expertise in big data, artificial intelligence, and the healthcare industry. Additionally, the company has established a high-quality medical advisory board.

Prior to this round of financing, Zhizhen Hulian had received tens of millions of yuan in combined investments from several well-known investment institutions, including Baidu, Shengjing Wanglian, Meihua Capital, Huajian Capital, Huayao Capital, and Daowei Capital.